Coexistence of craniopharyngioma and meningioma
Two rare cases and literature review
Guofang Liu, BA,a Linxi Su, MS,b Yan Xiang, BA,c Yun Liu, BA,a Shushu Zhang, BAa,*

Abstract
Most of the craniopharyngioma is considered to derive from residual epithelial cells during the craniopharyngeal canal degeneration. Meningioma accounting for the primary intracranial neoplasm is considered to be mainly derived from cells of arachnoid granulations. Nevertheless, rare cases show coexistence of craniopharyngioma and meningioma.

Case 1: A 43-year-old male patient referred to the hospital due to paroxysmal headache combined with blurred vision for 1 month. On physical examination, the visual acuity of left eye was poorer than that of the right eye. The visual acuity of the right eye near the nasal part showed defect.

MRI and pathological examination were performed. The patient received intracranial tumor resection. After surgery, the patient showed hormone disorder, followed by corresponding treatment. However, the patient was lost in the 6-month follow-up.

Case 2: The 64-year-old male patient presented to our department due to decline of visual acuity within 1 year combined with polydipsia (5,000 ml per day), polyuria and fatigue for 6 months. On physical examination, the bilateral visual acuity showed decline, especially the temporal part which was nearly hemiscotosis. MRI was performed. The adamantinomatous craniopharyngioma was diagnosed with the HE staining findings. The patient received intracranial resection. After surgery, the patient was in a deep coma condition, and was lost in the follow-up.

In this case study, we presented 2 patients with coexistence of craniopharyngioma and meningioma. In addition, a complete literature review was carried out to illustrate the studies on coexistence of craniopharyngioma and meningioma. Meanwhile, we tried to explain the possible mechanisms for such condition.

Abbreviations: CNS = central nervous system, MRI = magnetic resonance imaging. Keywords: collision tumor, craniopharyngioma, intracalvarium, meningioma.

1. Introduction
Craniopharyngioma is a rare benign tumor with central nervous system (CNS) involvement. Meningioma is a common tumor of CNS[1] presenting different MRI findings and pathological features. Coexistence of intracranial craniopharyngioma and meningioma, with an extremely lower prevalence, is a type of collision tumor that may be associated with the chemoradiation, embryogenic development and induction factors.[2] In this study, we analyzed the MRI findings and the pathological subtypes of 2 cases with coexistence of intracranial craniopharyngioma and meningioma. Meanwhile, a comprehensive literature research was performed. We aim to enhance our understanding on such type of collision tumor.

2. Case report
2.1. Case 1
A 43-year-old male patient referred to our hospital due to paroxysmal headache combined with blurred vision for 1 month. On physical examination, the visual acuity of left eye was poorer than that of the right eye. The visual acuity of the right eye near the nasal part showed defect. He reported no history of radiation, chemical exposure and trauma. Before surgery, the level of hormone was not available.

For the MRI findings of craniopharyngioma, there was a nodule (1.8 × 2.5 × 2.1 cm) in the saddle with an irregular shape. There were mixed T1 equal hypointensity signals, and the signals for T2 were mainly equal intensity signals combined with few high intensity signals. Significant and uneven enhancement was noticed after administration of Gd-DTPA. The meningioma was...
localized at the right sphenoidal crest with a size of $1.5 \times 1.0 \times 1.1$ cm. The T1 signals were even and equal, while T2 signals were slightly lower and even. Upon administration of Gd-DTPA, significant and even enhancement was noticed, together with tail signs in the meninges (Fig. 1A-E).

For the pathological findings, the craniopharyngioma (Fig. 1F) was adamantinomatous craniopharyngioma, which was classified into grade I according to the WHO classification.[1] The columnar cells in a cube or column pattern were arranged in a palisade profile, which was similar to the adamantoblasts in structure. The middle layer was pavement epithelium cells presenting a polygonal profile. There were sparse cells in a stellate profile in the internal layer. There was island like keratinization.

The meningioma (Fig. 1G) was meningothelial meningioma, and was of grade I according to the WHO classification. The tumor cells was well differentiated. The cytoplasm was of acidophilia. The boundary was vague. There were few karyokinises. Part of the cancer cells presented close swirl.

The patient received intracranial tumor resection after general anesthesia using intravenous injection of Midazolam (4mg), Propofol (6ml), Sufentanil (50μg), and cis-Tracurum (55mg), together with minipumping of Remifentanil (2mg) and propofol (100ml). The craniopharyngioma was mainly localized at the saddle area, and protruded to the posterior part. The tumor was in a grey-yellow color with uneven texture. There were no obvious cystic lesions. The tumor was adhered to the pituitary stalk, and was closely adjacent to the optic nerves and optic chiasma with no obvious boundaries. The meningioma was localized at the right sphenoidal crest, and the boundary was clear with an envelop. After surgery, the patient showed hormone disorder, followed by corresponding treatment. However, the patient was lost in the 6-month follow-up.

2.2. Case 2

The 64-year-old male patient presented to our department due to decline of visual acuity within 1 year combined with polydipsia (5000 ml per day), polyuria and fatigue for 6 months. On physical examination, the bilateral visual acuity showed decline, especially the temporal part which was nearly hemiscotosis. He reported no history of radiation, chemical exposure and trauma. The hormone levels were as follows: adrenocorticotropic hormone, $<5.00$ ng/l (4.8–48.8 ng/l); testosterone, 0.13nmol/L (4.94–32.01nmol/L); prolactin, 30.65 ng/ml (3.46–19.40 ng/ml); progesterone, 0.2 ng/ml ($<0.1$–0.2 ng/ml); estradiol, $<10.00$ pg/ml (11–44pg/ml); follicle stimulating hormone, 0.67mIU/ml (0.95–11.95mIU/ml).

For the MRI findings (Fig. 2A-C), there was a cystic/solid nodule in the saddle and the third ventricle. The shape was not regular, which showed a size of $2.0 \times 2.9 \times 2.6$ cm. Equal T1 signals and high T2 signals were observed in the cystic lesions. Slightly high T1 signals, together with mixed densities of T2 signals, were noticed in the solid lesions. Upon administration of Gd-DTPA, there was obvious enhancement at the margins of the solid and cystic lesions, and the enhancement was not even.

For the meningioma, there was a nodule in the right olfactory sulcus with a size of $1.5 \times 1.0$ cm. There were slightly high T1 signals, and few equal signals were observed at the central part. Upon administration of Gd-DTPA, there was obvious enhancement. The enhancement was even.

For the HE staining findings of craniopharyngioma (Fig. 2D), adamantinomatous craniopharyngioma was diagnosed. The columnar cells showed palisade arrangement, which formed the basal layer. The intermediate layer was pavement epithelium cell. The internal layer was sparse reticular cells, together with infiltration of inflammatory cells.

The cancer cells of meningioma (Fig. 2E) were of meningothelial type in meninges, of WHO grade I. The nucleus of cancer cells was in a round or ellipse profile. The boundary was not clear, and the cells were well differentiated. Few cells showed phases of karyokinises. The tumor cells showed a nest or lobulated growth. Partial cells showed arrangement in a swirl pattern, which were separated by the connective tissues containing blood vessels. Psammoma bodies were noticed.

The patient received intracranial resection after general anesthesia. The craniopharyngioma was localized beneath the third ventricle close to the saddle area in a grey color. The texture was slightly soft, and the blood supply was normal. The cystic
Lesions were noted. The tumor was adjacent to the third ventricle and hypothalamus. The meningioma was localized at the left olfactory sulcus. It was in a pink color, with hard texture. The blood supply was abundant, and the basement was localized in the olfactory sulcus, which protruded the left olfactory nerve outwards. The dura mater near the olfactory sulcus was hampered by the cancer tissues, and part of the bone absorption showed decrease. After surgery, the patient was in a deep coma condition, and was lost in the follow-up.

3. Discussion

Craniopharyngioma is a rare cranial tumor, with a prevalence of about 3% to 6% in China mainland,[3] and meningioma is a common CNS tumors. In the CNS tumor proposed by the WHO in 2016,[1] the craniopharyngioma was classified into grade I consisting of adamantinomatous craniopharyngioma and papillary craniopharyngioma, while the meningioma was classified into grade I-III. WHO classification of tumors of CNS in 2016 provides 15 distinct variants of meningioma of which nine variants correspond to WHO grade I, 3 variants correspond to WHO grade II, while other 3 variants correspond to the malignant type of WHO grade III meningiomas. This classification is based on growth pattern, mitotic index and brain invasion. To our best knowledge, rare cases simultaneously present these 2 tumors. There were only 6 cases between 1967 and 2018 in our literature research.[4-9] In this study, we presented 2 more cases with collision of craniopharyngioma (adamantinomatous craniopharyngioma) and meningioma (meningothelial meningioma).

Presence of at least 2 types of tumors in one cranial position was defined as coexisting tumor. It is really rare in the fields of neurosurgery.[9] Nowadays, 2 mechanisms are reported to explain this phenomenon, including:

1. tumor-tumor metastasis, defined as metastasis of cancer cells to another cancer. In addition, 2 of the following criteria[4][10] must be met: (a) the pathological findings were that the donor metastasis must be partially enclosed by a recipient benign primary neoplasm of the brain; (b) the metastatic neoplasm must originate from a known primary carcinoma.

2. Collision tumor, defined as coexistence of 2 primary tumors in one anatomical site. The 2 tumors may mutually contribute to the pathogenesis of each other.[11]

In a recent study, intracranial collision tumor accounted about one third of the coexistence tumor in skull.[2] According to the previous description,[12] the pathogenesis of collision tumor may be associated with the following aspects:

1. two tumors occurred at the same position or adjacent locations;
2. tumors occurred at the same position of the different tissues due to radiation, chemical exposure and trauma;
3. cranial tumor induced different tissue-derived tumor in the peripheral cerebral parenchyma or meningeal tissues;
4. the residual embryonic structure finally developed into different tissue-derived tumor.

Given the hyper-vascularization and relatively high incidence, meningioma is the most commonly implicated intracranial neoplasms in both metastasis and collision tumors.[6,13,14] In this study, a comprehensive analysis was performed for the collected cases (including the 2 cases in this study). As shown in Table 1, 3 cases showed collision tumor of no pathological subtype, 5 with adamantinomatous craniopharyngioma, 1 with meningioma of the transitional meningioma, 1 with angiomatous meningioma, 2 with meningothelial meningioma and 1 of uncertain type. All the 7 cases showed no histories of radiation,
| Case | Age (yrs) | Gender | Radiation, chemical exposure and trauma | Preoperative hormone | Adrenocorticotropic hormone, 17β[{(10–50)}; corticosteroid, 39.7 nmol/L{138–690}; follicle-stimulating hormone, 29.7 nmol/L{35–150}; luteinizing hormone, 28.8 nmol/L{11–67.5}; testosterone, 6.5 nmol/L{10.1–40.1}; follicle-stimulating hormone, 28.8 nmol/L{11–67.5}; estradiol, <120 pg/mL{90–120}; follicle-stimulating hormone, 0.67 mIU/mL{0.95–11.95}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/L{0.01–0.2}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/L{0.01–0.2}] | Adrenocorticotropic hormone, 17β[{(10–50)}; corticosteroid, 39.7 nmol/L{138–690}; follicle-stimulating hormone, 29.7 nmol/L{35–150}; luteinizing hormone, 28.8 nmol/L{11–67.5}; testosterone, 6.5 nmol/L{10.1–40.1}; follicle-stimulating hormone, 28.8 nmol/L{11–67.5}; estradiol, <120 pg/mL{90–120}; follicle-stimulating hormone, 0.67 mIU/mL{0.95–11.95}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/L{0.01–0.2}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/L{0.01–0.2}] |
| --- | --- | --- | --- | --- | --- | --- |
| 1 | 54 | Female | Not available | Not available | Not available | Not available |
| 2 | 65 | Male | None | Not available | Not available | Not available |
| 3 | 61 | Female | None | Not available | Not available | Not available |
| 4 | 81 | Female | None | Adrenocorticotropic hormone, 17β[{(10–50)}; corticosteroid, 39.7 nmol/L{138–690}; follicle-stimulating hormone, 29.7 nmol/L{35–150}; luteinizing hormone, 28.8 nmol/L{11–67.5}; testosterone, 6.5 nmol/L{10.1–40.1}; follicle-stimulating hormone, 28.8 nmol/L{11–67.5}; estradiol, <120 pg/mL{90–120}; follicle-stimulating hormone, 0.67 mIU/mL{0.95–11.95}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/L{0.01–0.2}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/L{0.01–0.2}] | Anterior border of pituitary gland, intra-sellar region-suprasellar region | Anterior border of pituitary gland, intra-sellar region-suprasellar region | Anterior border of pituitary gland, intra-sellar region-suprasellar region |
| 5 | 57 | Male | None | Testosterone, 5.21 ng/mL{4.30–25.56}; corticosteroid, 31.40 mg/mL{50–250}; lactotropin 557.2 mIU/L{86.0–324.0 mIU/L}; adrenocorticotropic hormone, 73.89 pg/mL{7.30–63.29 pg/mL}; testosterone, <0.09 nmol/L{9.90–27.80 nmol/L}; estradiol, <18.35 pg/mL{99.40–192.00 pg/mL} | Suprasellar region | Suprasellar region | Suprasellar region |
| 6 | 68 | Male | None | Lactotropin 557.2 mIU/L{86.0–324.0 mIU/L}; adrenocorticotropic hormone, 73.89 pg/mL{7.30–63.29 pg/mL}; testosterone, <0.09 nmol/L{9.90–27.80 nmol/L}; estradiol, <18.35 pg/mL{99.40–192.00 pg/mL} | Suprasellar region | Suprasellar region | Suprasellar region |
| 7 | 43 | Male | None | Not available | Suprasellar region | Suprasellar region | Suprasellar region |
| 8 | 67 | Male | None | Adrenocorticotropic hormone, <5.00 ng/mL{4.8–48.8}; testosterone, 0.13 nmol/L{4.94–32.01}; Prolactin, 30.65 mg/mL{3.46–19.40}; progesterone, 0.22 ng/mL{<0.1–0.2}; estradiol, <10.00 pg/mL{11–44}; follicle-stimulating hormone, 0.67 mIU/mL{0.95–11.95}; luteinizing hormone, 0.02 mIU/mL{1.14–8.75}; corticosteroid, 32.5 nmol/mL{8:00am 101.2–535.7, 4:00pm 79–477.8} | Intra-sellar region-suprasellar region-third ventricle | Intra-sellar region-suprasellar region-third ventricle | Intra-sellar region-suprasellar region-third ventricle | Intra-sellar region-suprasellar region-third ventricle | Intra-sellar region-suprasellar region-third ventricle | Intra-sellar region-suprasellar region-third ventricle | Intra-sellar region-suprasellar region-third ventricle |

**Table 1**

Clinopathological features of the 8 cases.
chemical exposure and trauma. One case showed no information available. Four cases showed no hormone level information before disease onset. Four cases showed hormonal response before disease onset. Pathological findings indicated no interaction between craniopharyngioma and meningioma as they were independent from each other. Besides, there was no partial coexistence between the tumors. Therefore, their coexistence may not be associated with tumor-tumor metastasis, and the 2 cancers were collision tumor. Before disease onset, the patient underwent no radiation and chemical exposure. Besides, there was no trauma. Thus, the possibility was excluded. For the origin of craniopharyngioma, the embryonal-rest hypothesis has been well acknowledged to explain its pathogenesis, but the meningioma must be originated from the arachnoid granulations. Therefore, it is not possible for the residual embryonic structure to develop into different tissue-derived tumors. Craniopharyngioma usually leads to hormonal disorder mediated by pituitary gland injury. It is now well-documented that meningiomas have endogenous and exogenous sex hormonal susceptibility. Three patients presented hormonal disorder, and 4 cases showed craniopharyngioma of adamantinomatous type. The meningioma showed different types. We speculated that the collision of craniopharyngioma and meningioma may be associated with the different tissue-derived tumors. Craniopharyngioma usually leads to hormonal disorder and may contribute to the reduction of postoperative complications. In summary, craniopharyngioma combined with meningioma is an extremely rare collision tumor. This would provide surgical significances in clinical practice. First, the collision should be considered. Meanwhile, we speculated that adamantinomatous craniopharyngioma may induce the pathogenesis of new types of meningioma, but it may be occasional.

**Author contributions**

**Conceptualization:** Guofang Liu, Linxi Su.

**Data curation:** Guofang Liu, Linxi Su.

**Formal analysis:** Linxi Su.

**Funding acquisition:** Linxi Su.

**Project administration:** Yan Xiang.

**Resources:** Yan Xiang, Yun Liu.

**Software:** Yan Xiang, Yun Liu.

**Supervision:** Yun Liu.

**Validation:** Yun Liu.

**Visualization:** Yun Liu.

**Writing – original draft:** Guofang Liu.

**Writing – review & editing:** Shushu Zhang.

**References**

[1] Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuroptahol 2016;131:803–20.

[2] Syed S, Karambizi DI, Baker A, et al. A comparative report on intracranial tumor-to-tumor metastasis and collision tumors. World Neurosurg 2018;116:454–63, e452.

[3] Shi XE, Wu B, Fan T, et al. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008;110:151–9.

[4] Nicola GC, Nuzzoli V. Multiple intracranial tumours of diverse origin in the same patient. Report of a case. J Neurol Sci 1967;4:595–9.

[5] Deen HG, Laws ER. Multiple primary brain tumors of different cell types. Neurosurgery 1981;8:20–5.

[6] Maiti F, Cappabianca P, Iaconetta G, et al. Simultaneous presentation of meningiomas with other intracranial tumors. Br J Neurosurg 2005;19:368–75.

[7] Della Pappa A, Del Moro G, Tosatto L, et al. Co-localisation of meningioma and craniopharyngioma mimicking a single skull base tumor in an elderly patient. J Neurooncol 2011;102:167–70.

[8] Wang C, Sun J, Shu Q, et al. Case Report collision tumor of meningioma and craniopharyngioma:a case report. Int J Clin Exp Pathol 2016;9:2552–7.

[9] Liu GP, Jin P, Yue Y, et al. Craniopharyngioma combined with meningioma: one case report and literature review. Chin J Neuroumed 2018;17:1151–2.

[10] Kochanski RB, Byrne N, Arvanitis L, et al. A rare intracranial tumor consisting of malignant anaplastic and papillary meningioma subtypes. Surg Neurol Int 2016;7:21.

[11] Kochanski R, Byrne N, Arvanitis L. A rare intracranial tumor consisting of malignant anaplastic and papillary meningioma subtypes. Surg Neurol Int 2016;7:64.

[12] Zhang D, Yu J, Guo Y, et al. An intraventricular meningioma and recurrent astrocytoma collision tumor: a case report and literature review. World J Surg Oncol 2015;13:37.

[13] Benedetto N, Perrini P, Scollato A, et al. Intracranial meningioma containing metastatic colon carcinoma. Acta Neuroch (Wien) 2007;149:799–803.

[14] Lanotte M, Benoch F, Panciato PP, et al. Systemic cancer metastasis in a meningioma: report of two cases and review of the literature. Clin Neurol Neurosurg 2009;111:87–93.

[15] Larkin SJ, Ansurge O. Pathology and pathogenesis of craniopharyngiomas. Pituitary 2013;16:9–17.

[16] Mei Y, Bi WL, Greenwald NF, et al. Genomic profile of human meningioma cell lines. PLoS ONE 2017;12(5):DOI:10.1371/journal. pone.0178322.

[17] Mende KC, Kellner T, Petersenn S, et al. Clinical situation, therapy, and follow up of adult craniopharyngioma-report from the German craniopharyngioma registry. J Clin Endocrinol Metab 2020;105:DOI:01;105(1).10.1210/clinem/dgzo433.

[18] Jazbiniak S, Kolenc D, Bozinak R, et al. Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Cniopharyngioma. Horm Res Paediatr 2020;DOI:10.1159/ 000507702.

[19] Jia Q, Qiu R, Mei F, et al. Interleukin-1β leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis. Metab Clin Exp 2019;101DOI:10.1080/02686897.2018.1472212.

[20] Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 1958;21:89–91.

[21] Peyre M, Gallard S, de Marcellus C, et al. Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Cniopharyngioma. Horm Res Paediatr 2020;DOI:10.1159/ 000507702.

[22] Portet S, Naoufli R, Tachon G, et al. Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment. Neuro Oncol Adv 2019;11: doi:10.1093/noan/alz003.

[23] Lu SN, Li CZ, Zha P, et al. Choice strategies of surgical approaches for craniopharyngiomas. Chin J Neuroumed 2017;13:1083–7.